SEC levies no fine against Kiromic BioPharma after material omissions self-disclosure
By 
Aaron Nicodemus2024-12-03T17:48:00
Kiromic BioPharma will pay no fine to the Securities and Exchange Commission (SEC) after self-reporting that it failed to disclose material information about two cancer drugs to investors.
Houston-based Kiromic raised $40 million in a July 2021 public offering to fund clinical trials for two cancer drugs, but failed to alert investors that the U.S. Food and Drug Administration (FDA) had placed holds on clinical trials two weeks before the offering, the SEC said Tuesday in a press release. The company failed to report the FDA holds in two SEC filings, and failed to correct statements made by executives in roadshow calls with investors, according to the agency.
The allegations came to light after two anonymous complaints were filed on the company’s whistleblower hotline in August 2021, the SEC said.
THIS IS MEMBERS-ONLY CONTENT
You are not logged in and do not have access to members-only content.
If you are already a registered user or a member, SIGN IN now.
Related articles
-
WebcastWebcast: The DOJ’s Corporate Whistleblower Program: What we’ve learned and how it can change in the future
We will discuss the critical role whistleblowers play in law enforcement, and how the DOJ has structured its program to incentivize people to come forward.
-
News BriefTeva Pharma to pay $450M to settle kickback, price-fixing allegations
Generic drug giant Teva Pharmaceuticals has agreed to pay $450 million to settle two cases brought by the Department of Justice (DOJ), including one alleging that co-pays it made on behalf of Medicare patients constituted illegal kickbacks, and a second action for alleged generic drug price fixing.
-
ArticlePharma, whistleblower lessons learned from $900M Biogen settlement
Experts discuss the ramifications of Biogen’s $900 million settlement for False Claims Act violations, including the $266.4 million whistleblower bounty in the case believed to be the largest single award under any government program.
More from Regulatory Enforcement
-
ArticleFalse Claims Act enforcement themes for 2026
The U.S. Department of Justice touted a record $6.8 billion in False Claims Act (FCA) recoveries in fiscal year 2025, much of that total stems from prior years’ cases and does not necessarily reflect the administration’s current enforcement direction.
-
ArticleFederal jury convicts former coal executive in Egypt-linked coal FCPA case
A former vice president of an American coal company was convicted by a federal jury for his part in an international bribery and money laundering scheme. The conviction represents an anomoly in the Trump administration’s handling of Foreign Corrupt Practices Act (FCPA) cases launched under former President Joe Biden.
-
ArticleU.K. financial regulator cuts cases to focus on investigations that achieve results
The U.K. financial regulator has dropped 100 investigations without action over the past three years, but compliance should expect a refocus of resources rather than a retreat from enforcement.